Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients

Endocrine-Related Cancer

Volumn 17, Issue 4, 2010, Pages 885-895

  Crnalic, S ^a   Hornberg E ^a   Wikstrom P ^a   Lerner, U H ^a   Tieva, A ^a   Svensson, O ^a   Widmark, A ^a   Bergh, A ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; CELL NUCLEUS RECEPTOR; CHROMOGRANIN A; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE METASTASIS; CELL NUCLEUS; CELL PROLIFERATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PROGNOSIS; PROSTATE CANCER; SCORING SYSTEM; TUMOR CELL;

AGED; AGED, 80 AND OVER; APOPTOSIS; BONE NEOPLASMS; CASPASE 3; CELL GROWTH PROCESSES; CELL NUCLEUS; CHROMOGRANIN A; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 78649888652     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0059     Document Type: Article

References (35)

1. Abu EO, Horner A, Kusec V, Triffitt JT & Compston JE 1997 The localization of androgen receptors in human bone. Journal of Clinical Endocrinology and Metabolism 82 3493-3497. (doi:10.1210/jc.82.10.3493)
2. Asmann YW, Kosari F, Wang K, Cheville JC & Vasmatzis G 2002 Identification of differentially expressed genes in normal and malignant prostate by electronic profiling of expressed sequence tags. Cancer Research 62 3308-3314.
3. Bonkhoff H & Berges R 2010 From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70 100-112. (doi:10.1002/pros. 21042)
4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
5. Chen Y, Sawyers CL & Scher HI 2008 Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology 8 440-448. (doi:10.1016/j.coph.2008.07.005)
6. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B & Blute ML 2002 Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 95 1028-1036. (doi:10.1002/cncr.10788)
7. Dearnaley DP, Mason MD, Parmar MK, Sanders K & Sydes MR 2009 Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncology 10 872-876. (doi:10.1016/S1470- 2045(09)70201-3)
8. Denmeade SR & Isaacs JT 2002 A history of prostate cancer treatment. Nature Reviews. Cancer 2 389-396. (doi:10.1038/nrc801)
9. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F & Thalman G 2010 Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 70 875-882. (doi:10.1002/pros.21121)
10. Gao J, Arnold JT & Isaacs JT 2001 Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Research 61 5038-5044.
11. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ et al. 2009 A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 69 2305-2313. (doi:10.1158/0008- 5472.CAN-08-3795)
12. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ & Sutherland RL 2001 Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Research 61 423-427.
13. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H & Hittmair A 1995 Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Research 55 3068-3072.
14. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P et al. 2004 Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. American Journal of Pathology 164 217-227. (Pubitemid 38364606)
15. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB et al. 2009 Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research 69 16-22. (doi:10.1158/0008-5472.CAN-08-2764)
16. Johansson A, Jones J, Pietras K, Kilter S, Skytt A, Rudolfsson SH & Bergh A 2007 A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Prostate 67 1664-1676. (doi:10.1002/pros.20657)
17. Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K & Murai M 2005 Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. Clinical Cancer Research 11 5590-5594. (doi:10.1158/1078-0432.CCR-04-2561)
18. Li R, Wheeler T, Dai H, Frolov A, Thompson T & Ayala G 2004 High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. American Journal of Surgical Pathology 28 928-934. (doi:10.1097/00000478-200407000-00013)
19. Maitland NJ & Collins AT 2008 Prostate cancer stem cells: a new target for therapy. Journal of Clinical Oncology 26 2862-2870. (doi:10.1200/JCO.2007.15.1472)
20. Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Chang C, Messing EM & Wu JH 2001 Localization of androgen receptor expression in human bone marrow. Journal of Pathology 193 361-366. (doi:10.1002/1096-9896(0000)9999: 9999〈::AID-PATH803〉3.0.CO;2-W)
21. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD & Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 68 4447-4454. (doi:10.1158/0008-5472.CAN-08-0249)
22. Morrissey C & Vessella RL 2007 The role of tumor microenvironment in prostate cancer bone metastasis. Journal of Cellular Biochemistry 101 873-886. (doi:10.1002/jcb.21214)
23. Ohlson N, Wikstrom P, Stattin P & Bergh A 2005 Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 62 307-315. (doi:10.1002/pros.20139)
24. Ohlson N, Bergh A, Nygren K, Stattin P & Wikstrom P 2006 The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome. European Urology 49 675-684. (doi:10.1016/j.eururo.2005.10.024)
25. Ohlson N, Bergh A, Stattin P & Wikstrom P 2007 Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels. Prostate 67 32-40. (doi:10.1002/pros.20480)
26. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr & Corey E 2003 Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97 1211-1216. (doi:10.1002/cncr.11178)
27. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P & Vessella RL 2003 Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Human Pathology 34 646-653. (doi:10.1016/S0046-8177(03) 00190-4)
28. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA et al. 2004 Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Research 64 9209-9216. (doi:10.1158/0008-5472.CAN-04-2442)
29. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG & Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 66 2815-2825. (doi:10.1158/0008-5472.CAN-05-4000)
30. Stege R, Grande M, Carlstrom K, Tribukait B & Pousette A 2000 Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clinical Cancer Research 6 160-165.
31. Sweat SD, Pacelli A, Bergstralh EJ, Slezak JM, Cheng L & Bostwick DG 1999 Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery. Journal of Urology 161 1233-1237. (doi:10.1016/S0022-5347(01)61645-8)
32. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al. 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 787-790. (doi:10.1126/science.1168175)
33. Wikstrom P, Lindahl C & Bergh A 2005 Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate 62 148-164. (doi:10.1002/pros.20123)
34. Wikstrom P, Ohlson N, Stattin P & Bergh A 2007 Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy. Prostate 67 1277-1284. (doi:10.1002/pros.20569) (Pubitemid 47435775)
35. Wikstrom P, Marusic J, Stattin P & Bergh A 2009 Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 69 799-809. (doi:10.1002/pros.20927)